Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Renovis
South San Francisco, California, United Statesevotec.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Renovis was developing prescription drugs for neurological diseases and cancer. Their lead programs included VR1 antagonists for pain, urinary incontinence, and asthma, and P2X7 antagonists for rheumatoid arthritis, irritable bowel syndrome, and chronic obstructive pulmonary disease. Both programs were expected to enter human clinical trials in 2008.
- Therapeutic areas
- GastroenterologyPulmonologyNephrologyImmunologyOncologyNeurology
- Modalities
- Small molecules
- Industry
- Biotech
02
Partnerships
Beyond the preview
Go deeper on Renovis.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Renovis.